Businesswire News Releases

Dec 10, 2023 05:31 ET
Teoayeah’s Christmas Gift List for All Kids (12/11-12/24)
The annual Christmas season is just around the corner and the festive spirit fills the air. In order to give every child a satisfying Christmas gift, Teoayeah has prepared the safest and most reliable simulation electric toy cars for kids with various styles and functions. Thanks to the remaining offers from Black Friday and Cyber Monday, there are now some great value specials at record low prices....
Dec 10, 2023 01:00 ET
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome (SS). The results were presented at the ASH 2023 Annual Meeting, in San Diego, California....
Dec 09, 2023 19:21 ET
Belgian, Port Houston and Partners Sign Memorandum of Understanding on Energy Transition Cooperation
Today, H.E. Alexander De Croo, Prime Minister of Belgium, witnessed the signing of a Memorandum of Understanding on Energy Transition Cooperation between three Belgian and three Houston-based partners to boost transatlantic cooperation on the green transition. The Center for Houston's Future, Waterstofnet, Port Houston, the Port of Antwerp-Bruges, Exmar, and the Blue Sky Maritime Coalition agreed to explore a win-win partnership around an import-export coalition for renewable and low-carbon molecules, a green shipping corridor and the exchange of best practices, knowledge and research....
Dec 09, 2023 19:00 ET
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (
Dec 09, 2023 17:15 ET
Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting
Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced positive new data that suggest its investigational high-precision cell therapies, Orca-T and Orca-Q, have the potential to deliver improved clinical outcomes across different age ranges, donor types and conditioning regimens relative to existing standard of care allogeneic hematopoietic stem cell transplants (alloHSCT). The results presented at the 65th American Society of Hematology (ASH) Annual Meeting showed promi...
Dec 09, 2023 17:00 ET
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk
Bristol Myers Squibb (NYSE: BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS) (
Dec 09, 2023 14:25 ET
LPSN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of LivePerson, Inc. (NASDAQ: LPSN) securities between May 10, 2022 and March 16, 2023, both dates inclusive (the “Class Period”), have until January 30, 2024 to seek appointment as lead plaintiff of the ...
Dec 09, 2023 12:30 ET
Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma
Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Corne...
Dec 09, 2023 12:00 ET
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR)...
Dec 09, 2023 12:00 ET
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study in a poster presentatio...
Dec 09, 2023 11:52 ET
Port Houston Regular Commission Meeting
The Port Commission of the Port of Houston Authority will hold its Regular Commission Monthly Meeting on Tuesday, December 12, 2023, beginning at 9:15 a.m. A quorum of the Port Commission, along with executive leadership, will be present in the boardroom of the Port Houston Executive Office Building, located at 111 East Loop North, Houston, TX 77029....
Dec 09, 2023 11:31 ET
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Reso
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or “bluebird”) today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease through five years of follow-up (median 35.5 months, range 0.3-61 months). Data were highlighted in a press briefing at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition and will be presented in an oral presentation on Monday, December 11, 2023 at 4:30 p.m. Paci...
Dec 09, 2023 11:30 ET
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab-kxwh) in previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful bleed control in babies up to 12 months of age and was well tolerated. The new data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023 in San Dieg...
Dec 09, 2023 05:06 ET
AYA Platform of Enjinstarter Granted Virtual Asset Service Provider Licence by Dubai’s Virtual Assets Regulatory Authority
Web 3 Innovations FZE (trading as AYA), the Dubai entity of Enjinstarter, a leading Web3 launchpad and advisory company, today announced that it has been granted a Virtual Asset Service Provider (VASP) licence from Dubai’s Virtual Assets Regulatory Authority (VARA) to provide Virtual Asset Management and Investment Services. The licence remains non-operational until the company fully satisfies all remaining conditions and select localisation requirements defined by VARA, following which it will be able to commence operations, subject to regulatory reverification and approval....
Dec 08, 2023 21:01 ET
NOVA Shareholder News: Johnson Fistel Encourages Sunnova Energy Shareholders with Losses to Contact the Firm Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Sunnova Energy International Inc. (NYSE: NOVA), any of its executive officers or others violated securities laws by m...
Dec 08, 2023 21:00 ET
CAPSTONE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Capstone Green Energy Corporation and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Capstone Green Energy Corporation (“Capstone” or the “Company”) (NASDAQ: CGRN) (OTC: CGRNQ) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Capstone securities between June 14, 2021 and September 22, 2023, both dates inclusive (the “Class Period”). Investors have until December 12, 2023 to apply to the Court to be appointed as lead plaintiff in t...
Dec 08, 2023 21:00 ET
ESTEE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against The Estee Lauder Companies Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against The Estee Lauder Companies Inc. (“Estee” or the “Company”) (NYSE: EL) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Estee common stock between August 18, 2022 and May 2, 2023, both dates inclusive (the “Class Period”). Investors have until February 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit....
Dec 08, 2023 21:00 ET
NIKOLA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nikola Corporation and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Nikola Corporation (“Nikola” or the “Company”) (NASDAQ: NKLA) in the United States District Court for the District of Arizona on behalf of all persons and entities who purchased or otherwise acquired Nikola securities between February 24, 2022 and September 7, 2023, both dates inclusive (the “Class Period”). Investors have until December 12, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit....
Dec 08, 2023 20:15 ET
Air Force's Trey Taylor Named 2023 Paycom Jim Thorpe Award Winner
Trey Taylor of the United States Air Force Academy Falcons has been named the 2023 Paycom Jim Thorpe Award Winner. The award is given to the top defensive back in college football based on performance on the field, athletic ability and character. The announcement was made live on The Home Depot College Football Awards on ESPN. Taylor received the 2023 honor on behalf of Oklahoma Sports Hall of Fame and presenting sponsor Paycom....
Dec 08, 2023 19:51 ET
Newmont Announces Successful Early Tender Results for the Exchange Offers and Consent Solicitations
Newmont Corporation (Newmont or the Company) announced today, in connection with the previously announced offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes (the “Existing Newcrest Notes”) issued by Newcrest Finance Pty Limited, a wholly owned subsidiary of Newmont (“Newcrest Finance” and, together with Newmont, the “Issuers”), for (1) up to $1.65 billion aggregate principal amount of new notes to be issued by the Issuers (the “New Newmont Notes”) and (2) cash, and related consent solicitations (each, a “Consent Solicitation” a...